Mimedx (MDXG) Other Accumulated Expenses (2011 - 2026)
Mimedx recorded quarterly Other Accumulated Expenses of $6.1 million in Q1 2026, up 4.56% quarter-over-quarter from $5.8 million in Q4 2025, and up 36.51% year-over-year from $4.4 million in Q1 2025.
Mimedx's Other Accumulated Expenses history runs 16 years deep, the most recent figure standing at $6.1 million for Q1 2026.
- In Q1 2026, Other Accumulated Expenses rose 36.51% year-over-year to $6.1 million; the TTM figure through Mar 2026 stood at $6.1 million (up 36.51% YoY), while the FY2025 annual figure was $5.8 million, up 28.47% from the prior year.
- Other Accumulated Expenses came in at $6.1 million for Q1 2026 at Mimedx, up from $5.8 million in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $6.1 million in Q1 2026 to a low of $1.6 million in Q1 2022.
- A 5-year average of $3.1 million and a median of $2.6 million in 2024 frame the typical range for Other Accumulated Expenses.
- Across the five-year window, Other Accumulated Expenses dropped 6.04% in 2022 and surged 126.92% in 2024, its largest moves.
- Mimedx's Other Accumulated Expenses stood at $1.8 million in 2022, then surged by 57.8% to $2.9 million in 2023, then soared by 55.74% to $4.5 million in 2024, then increased by 28.47% to $5.8 million in 2025, then increased by 4.56% to $6.1 million in 2026.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $6.1 million, $5.8 million, and $4.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Mimedx | 530.69 Mn | 370.92 Mn | 41.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.05 Mn |
| Dec 31, 2025 | 5.79 Mn |
| Sep 30, 2025 | 4.42 Mn |
| Jun 30, 2025 | 3.41 Mn |
| Mar 31, 2025 | 4.44 Mn |
| Dec 31, 2024 | 4.51 Mn |
| Sep 30, 2024 | 2.59 Mn |
| Jun 30, 2024 | 2.07 Mn |
| Mar 31, 2024 | 4.07 Mn |
| Dec 31, 2023 | 2.89 Mn |
| Sep 30, 2023 | 1.85 Mn |
| Jun 30, 2023 | 2.06 Mn |
| Mar 31, 2023 | 1.79 Mn |
| Dec 31, 2022 | 1.83 Mn |
| Sep 30, 2022 | 1.96 Mn |
| Jun 30, 2022 | 1.78 Mn |
| Mar 31, 2022 | 1.56 Mn |
| Dec 31, 2021 | 1.57 Mn |
| Sep 30, 2021 | 1.70 Mn |
| Jun 30, 2021 | 1.68 Mn |
| Mar 31, 2021 | 1.66 Mn |
| Dec 31, 2020 | 1.47 Mn |
| Sep 30, 2020 | 1.36 Mn |
| Jun 30, 2020 | 1.42 Mn |
| Mar 31, 2020 | 2.42 Mn |
| Dec 31, 2019 | 1.40 Mn |
| Sep 30, 2019 | 1.68 Mn |
| Jun 30, 2019 | 1.53 Mn |
| Mar 31, 2019 | 2.40 Mn |
| Dec 31, 2018 | 1.82 Mn |
| Dec 31, 2017 | 647,000.00 |
| Sep 30, 2017 | 358,000.00 |
| Jun 30, 2017 | 550,000.00 |
| Mar 31, 2017 | 587,000.00 |
| Dec 31, 2016 | 1.48 Mn |
| Sep 30, 2016 | 3.30 Mn |
| Jun 30, 2016 | 1.99 Mn |
| Mar 31, 2016 | 1.25 Mn |
| Dec 31, 2015 | 533,000.00 |
| Sep 30, 2015 | 14,000.00 |
| Jun 30, 2015 | 461,000.00 |
| Mar 31, 2015 | 746,000.00 |
| Dec 31, 2014 | 716,000.00 |
| Sep 30, 2014 | 251,578.00 |
| Jun 30, 2014 | 175,247.00 |
| Mar 31, 2014 | 192,522.00 |
| Dec 31, 2013 | 123,000.00 |
| Sep 30, 2013 | 155,077.00 |
| Jun 30, 2013 | 252,343.00 |
| Mar 31, 2013 | 167,600.00 |
| Dec 31, 2012 | 21,583.00 |
| Sep 30, 2012 | 78,634.00 |
| Jun 30, 2012 | 69,981.00 |
| Dec 31, 2011 | 6,620.00 |